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a b s t r a c t
It is unclear if HIV-1 variants lose the ability to prime naïve CD8þ cytotoxic T lymphocytes (CTL) during
progressive, untreated infection. We conducted a comprehensive longitudinal analysis of viral evolution
and its impact on primary and memory CD8þ T cell responses pre-seroconversion (SC), post-SC, and
during combination antiretroviral therapy (cART). Memory T cell responses targeting autologous virus
variants reached a nadir by 8 years post-SC with development of AIDS, followed by a transient
enhancement of anti-HIV-1 CTL responses upon initiation of cART. We show broad and high magnitude
primary T cell responses to late variants in pre-SC T cells, comparable to primary anti-HIV-1 responses
induced in T cells from uninfected persons. Despite evolutionary changes, CD8þ T cells could still be
primed to HIV-1 variants. Hence, vaccination against late, mutated epitopes could be successful in
enhancing primary reactivity of T cells for control of the residual reservoir of HIV-1 during cART.
& 2013 Published by Elsevier Inc.
Introduction
CD8þ cytotoxic T lymphocytes (CTL) are a crucial component of
the immunological defense against human immunodeﬁciency
virus type 1 (HIV-1) infection (Bangham, 2009). The appearance
of CTL responses is associated with the early decline of plasma
viremia during HIV-1 infection (Koup et al., 1994). Depletion of
CD8þ T cells in the non-human primate model results in enhanced
disease progression, supporting the protective role of these cells
(Schmitz et al., 1999). Long term control of both HIV-1 and simian
immunodeﬁciency virus (SIV) infections is associated with a
broad and high magnitude CTL response (Pandrea et al., 2011;
Saez-Cirion et al., 2007), particularly to Gag epitopes (Berger et al.,
2011; Kiepiela et al., 2007; Rolland et al., 2008). However, despite
the establishment of HIV-1-speciﬁc CTL responses during early
HIV-1 infection, they fail to control persistent, chronic HIV-1
infection. A hallmark of HIV-1 pathogenesis is the ability of the
virus to escape host CTL responses through mutations within and
adjacent to CTL epitopes during the early and chronic phases of
the infection (Allen et al., 2002, 2000; Leslie et al., 2004; O’Connor
et al., 2002). HIV-1 prophylactic and therapeutic vaccine strategies
have yet to establish protective CD8þ CTL responses to overcome
the propensity of the virus to undergo escape mutations.
The breadth and magnitude of CD8þ T cell responses are
thought to be critical indicators in the control of HIV-1 infection
as well as prevention of AIDS (Baker et al., 2009; Deeks and
Walker, 2007). Therefore, the induction of strong and broadly
reactive memory CTL responses is believed to be necessary to
respond to the diverse viral sequences generated during the
course of infection. Indeed, the failure of the STEP prophylactic
vaccine trial has been linked in part to induction of limited CTL
responses and failure to cross-react with circulating viral strains
(Barouch and Korber, 2010; Corey et al., 2009). There is also a
correlation between the larger number of T cell responses target-
ing different SIV proteins and control of viral load in non-human
primates (Liu et al., 2009; Reynolds et al., 2008). Importantly, the
plasticity of the T cell receptor (TCR) and its ability to recognize
wild-type and variant epitopes are suggested to be critical in viral
control (Ladell et al., 2013). Moreover, the ability of TCR usage to
modulate the protective role of MHC class I alleles has been
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recently described to be more important than the magnitude,
polyfunctionality and avidity of T cell responses (Chen et al., 2012).
The continuous debate highlighted above emphasizes the impor-
tance of understanding the mechanisms underlying the ability of
CD8þ T cell responses to control HIV-1 replication for the design of
successful vaccine strategies.
Mechanisms promoting the establishment of escape mutations
and thus evasion of clearance of HIV-1-infected cells by CTL
include interaction defects between a viral epitope and its cognate
MHC class I molecule or between an MHC class I molecule/epitope
complex and its T cell receptor (TCR) (Leslie et al., 2004) and
impairment at the level of epitope processing (Allen et al., 2004;
Draenert et al., 2004; Yokomaku et al., 2004). It is imperative to
overcome these complications of natural infection in order to
design HIV-1 vaccines capable of eliciting antiviral immunity
targeting the diverse viral strains circulating during the course of
infection and spreading from person to person. We have pre-
viously shown the generation of broadly reactive and polyfunc-
tional primary CD8þ T cell responses from HIV-1 naïve adults
against HIV-1 and other viral epitopes (Colleton et al., 2009).
Optimal priming of CD8þ T cells requires maturation of DC with
CD40L and IFN-γ. This maturation protocol generates IL-12-
producing DC (Fan et al., 2007) with increased expression of
activation and costimulatory molecules. These factors are involved
in activation of memory antigen-speciﬁc CD8þ T cell memory
responses and are likely involved in priming of CD8þ T cells (Prlic
et al., 2007). These in vitro, T cell memory and priming models
represent a promising approach to evaluate the immunogenicity of
potential HIV-1 epitopes for vaccine design (Malaspina et al.,
2011).
To better understand the relationship between viral evolution
and its impact/effect on primary and memory responses, we
examined autologous HIV-1 gag, env, and nef sequences derived
at multiple points up to approximately 12 years post-
seroconversion (SC) in a participant in the Multicenter AIDS
Cohort Study (MACS) (Detels et al., 2012; Kaslow et al., 1987).
The breadth and magnitude of primary T cell responses were
compared to memory, recall T cell responses observed early and
late during infection as well as during cART. Our results reveal
memory T cell responses speciﬁc for prior and contemporaneous
HIV-1 variants. We further demonstrate the development of strong
primary responses in pre-SC naïve T cells to naturally evolving
HIV-1 variant sequences in an entirely autologous system. These
primary CD8þ T cell responses were of similar breadth to memory
responses and of higher magnitude, thus supporting the use of
such models in immunotherapy of HIV-1 infection in persons
on cART.
Results
Clinical and virologic characteristics of the study participant
Study subject 8 enrolled in the MACS in November, 1984,
3.2 years prior to SC to HIV-1. He was negative for both hepatitis
B and C viruses throughout the period of study. PBMC and plasma
samples were collected biannually from the time of enrollment.
Within the ﬁrst 3 years after SC (early post-SC: 0–2.8 years), the
number of CD4þ T cells decreased and the number of CD8þ T cells
increased, with an inversion in the CD4:CD8 T cell ratio (Fig. 1).
Viral load increased sharply to 7.8104 RNA copies/ml at the ﬁrst
SC visit (0.3 years) and then reached a set point ranging from
23,092 to 39,608 RNA copies/ml up to 2.8 years. For the next
4.4 years (late post-SC: 3.3–7.8 years), the numbers of CD4þ T cells
decreased, reaching 200 cells/mm3 6.1 years post-SC (Stage 3 HIV-
1 infection, AIDS) (Schneider et al., 2008) while CD8þ T cells
continued to increase. This decline in CD4þ T cells was associated
with a rise in viral load that began approximately 3.8 years post-
SC. A decline in viral load to a nadir of 80,470 copies/ml at 7.8 years
post-SC was observed after development of AIDS and before
initiation of cART at 8.3 years post SC. Overall, we observed a
negative correlation between HIV-1 viral load and CD4þ T cell
counts (p¼0.001), as well as a positive correlation between viral
load and CD8þ T cell counts (p¼0.0004) before cART. Imposition
of cART led to a decline in viral load to o200 RNA copies/ml
during the ﬁrst 1.8 years (early ART: 8.3–10.1 years). HIV-1 plasma
viremia was maintained between o20 and 119 copies/ml through
the next 10 years (late post-ART: 412.4 years). During this period
of viral suppression, an increase in the CD4þ T cell count was
observed with levels ranging between 266 and 587 cells/mm3,
with a concurrent decrease in CD8þ T cell counts (Fig. 1).
Taken together, these data demonstrate a typical course of HIV-1
infection from SC through development of AIDS, and recovery
on cART. Consequently, we chose to use this participant in
our longitudinal analysis of viral evolution and immunological
responses to autologous HIV-1.
Dynamics of viral evolution and epitope variants
We examined the longitudinal changes in HIV-1 genes from
subject 8 to deﬁne the effects of immune pressure during chronic,
untreated infection and during ART. We sequenced 12, 16, and
9 time points that spanned 410 years of infection for gag-p17/-
p24, env, and nef genes, respectively. We next determined the
pairwise diversity and divergence from the founder virus popula-
tion at each time point. As expected (Shankarappa et al., 1999),
viral diversiﬁcation and divergence in each HIV-1 gene gradually
increased with time (Fig. 2).
Diversity accumulated linearly in gag p17 (Fig. 2A) and gag p24
(Fig. 2B) and then shrunk, with the peak being about 4.9 years
post-SC. Notably, diversiﬁcation of env (Fig. 2C) and nef (Fig. 2D)
proceeded faster than that of gag. A linear increase in diversity was
observed until 6.1 years post-SC in env, when X4 viruses ﬁrst
appeared, and then diversity began to shrink (Shankarappa et al.,
1999). Diversiﬁcation of the nef gene followed a different pattern,
with diversiﬁcation appearing to slow appreciably before 4 years
of infection, and, following a transient contraction, increased
slowly thereafter. No clear plateau in divergence from the founder
strain was noted in nef (Fig. 2C).
In summary, the circulating viral populations within our study
participant show increasing divergence from the founder virus.
Interestingly, we observed a signiﬁcant correlation between viral
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Fig. 1. Clinical course of HIV-1 infection in the study participant. Plasma viral load
(red line), CD4þ (green line) and CD8þ T (blue line) cell counts in subject 8 are
shown. The study participant developed AIDS as per CDC guidelines at year
6.2 post-SC. cART was administered at 8.4 years post-SC. Years post-SC (x-axis)
include early, late, early cART and late cART time points deﬁned as follow: 0–2.8
years post-SC, 3.3–7.8 years post-SC, 8.3–10.1 years post-SC, and 412.4 years post-
SC, respectively. SC, seroconversion.
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load and viral divergence (po0.01) and diversity (p¼0.05) up
through 6.6 years post-SC, wherein viral load began a rapid decline
prior to cART.
Autologous HIV-1 peptide binding afﬁnity to MHC class I
The strength of peptide binding to MHC class I is a key
determinant in CTL epitope immunogenicity (Goulder and Watkins,
2008). We therefore identiﬁed known HLA A*0201- and B*0702-
restricted HIV-1 CTL epitopes in autologous sequences from subject
8 based on previously established immunologic activity (Yusim,
2004). We also predicted additional HLA A*0201- and B*0702-
restricted epitopes using the BioInformatics and Molecular Analysis
Section (BIMAS) computational model (Parker et al., 1994). Accord-
ingly, we identiﬁed 12 peptide families consisting of the Gag, Env, or
Nef founder epitopes and their corresponding autologous variants
that evolved during infection (Table 1). Epitope variants are referred
to in Table 1 in order of their evolution in our study participant.
In vitro ﬂuorescence polarization binding assay was performed
for each variant (Buchli et al., 2005). We also evaluated the
predicted MHC-restricted binding afﬁnity of variant epitope
sequences within Gag, Env, and Nef by netMHCpan (Hoof et al.,
2009; Nielsen et al., 2007). Lower experimental log IC50 values and
netMHCpan scores (IC50) correspond to actual and predicted
higher peptide:MHC binding afﬁnity, respectively. Signiﬁcant
positive correlations were found between observed and predicted
MHC class I binding in the following families: SLFNTVATL (Gag
p1777–85), TLNAWVKVV (Gag p2419–27), RMYSPTSIL (Gag p24143–151),
TLEQVVKKL (Env gp160/120341–349), FPVRPQVPL (Nef68–76),
TPGPGTRYPL (Nef128–137), and VLVWRFDSSL (Nef180–189) (Table 1).
To evaluate the relationship between MHC binding and T cell
responses to autologous epitope variants, we ﬁrst determined the
frequency of epitope variants with different binding capacities
during three distinct periods post-SC: early post-SC (0–2.8 years),
late post-SC (3.25–7.8 years), and at early cART (8.3–10.1 years)
(Fig. S1). Three binding afﬁnity categories of peptide variants to
MHC class I molecules are referred to based on the log IC50
obtained by the FP assay: high afﬁnity binderso3.7, medium
afﬁnity binderso4.7, low afﬁnity binderso5.5 and no afﬁnity
binderso6.0. Results in Fig. 3 show: (1) medium binders
constituted 497% of the Gag epitope pool at all three time points,
(2) within Env contemporaneous epitopes, medium binders made
up only 4% of the epitope pool early post-SC, but increased to
19.7% and 45.1% during late post-SC and early ART, respectively;
frequency of high and low binders gradually decreased with this
increase in medium binders, and (3) the frequency of Nef variants
with medium binding afﬁnity ranged from 50% to 70% through
time with no trend in the ﬂuctuation of low and high binder
frequencies.
Taken together, peptide variants with medium binding afﬁnity
were more frequent than variants with low or high binding afﬁnity
during the course of the study. We observed 3 distinct patterns of
evolutionary changes in epitope families (Fig. S1): (1) a complete
switch in the dominant form of the epitope (e.g., RMYSPTSIL and
RPMTWKGAL families), (2) no change in the dominant form of the
epitope or a transient change in dominance that eventually resulted
in the founder variant being more dominant (e.g., SLYNTVATL,
TLNAWVKVV, SPRTLNAWV, and FPVRPQVPL families), or (3) multiple
variants at each time point with no observable dominant variant
(e.g., RPNNNTRKSI, TLEQVVKKL, TPGPTRYPL, PLTFGWCFKL, VLVWR-
FDSSL families).
Impact of peptide: MHC binding afﬁnity on the breadth of memory
T cell responses to autologous contemporaneous HIV-1 peptide
sequences
To better understand the impact of CTL epitope variation and
the frequency of different binders on corresponding T cell
responses, we longitudinally evaluated HIV-1 speciﬁc T cell
responses targeting autologous known and predicted CTL epitope
variants. Autologous PBMC were used as responder cells in IFN-γ
ELISPOT to measure memory (recall) T cell responses stimulated
by DC-loaded with peptide sequences. We ﬁrst calculated the
percentage of naturally occurring Gag, Env, and Nef peptide
variants yielding positive in vitro T cell responses at early post-
SC, late post-SC, or at ART time points as a function of the total
p17 p24
C2V5 nef
Fig. 2. Dynamics of genetic diversity and divergence of HIV-1 in the study participant. (○) Divergence and () diversity of (A) gag p17, (B) gag p24, (C) env and (D) nef are
plotted (y-axis) for each gene during the course of HIV-1 infection. The study participant developed AIDS at year 6.2 post-SC and cART was administered at 8.4 years post-SC
(vertical lines). Trends in pairwise distance diversity and divergence from the founder virus are plotted through time from seroconversion to 10.1 years post-SC. SC,
seroconversion.
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Table 1
Evolving HIV-1 peptide sequences and their HLA-matched predicted and experimental afﬁnity binding scores.
MHC class I binding
HIV-1 proteina (epitope position) Sequence b HLAc restriction netMHCpand log IC50e Correlation coefﬁcient p value
Gag
p17 77–85 SLFNTVATL A*0201 139.2 3.81 0.9777 0.0002
SLFNTVAAL Potential 41.9 3.84
SLFNTVATP Potential 13108 5.24
SLFSTVAT’L Potential 106.9 3.66
SLFNTIATL Potential 55.12 3.92
SLYNTVATL A*0201 223.2 3.86
p24 16–24 SPRTLNAWV B*0702 36.4 4.18 0.0357 NSf
SPRTLDAWV Undeﬁned 102.5 4.38
SPRALNAWV Undeﬁned 24.4 4.07
PPRTLNAWV Undeﬁned 1221 4.22
SPRPLNAWV Undeﬁned 20 4.18
SPRTLSAWV Undeﬁned 36.9 6.08
p24 19–27 TLNAWVKVV A*0201 113.7 4.16 0.8439 0.034
TLDAWVKVV Potential 85.6 4.30
ALNAWVKVV Potential 42.7 3.93
PLNAWVKVV Potential 2854.1 4.81
TLSAWVKVV Potential 105.4 4.18
p24 143–151 RMYSPTSIL Potential 173.1 4.34 0.9738 0.0132
RMYSPISIL Potential 87.7 3.83
RMYSPASIL Potential 281 4.78
RMYSPVSIL Potential 123.8 3.92
Env gp160/120
298–307 RPNNNTRKSI B*0702 14.7 3.56 0.0901 NS
RPNNNTRRSI Undeﬁned 9.3 3.99
RSNNNTRKSI Undeﬁned 3120.83 4.33
RPNNNTRKST RS9 B*07 130 4.04
RPNNSTRKSI Undeﬁned 12.6 3.87
RPNNDTRKSI Undeﬁned 23.9 3.85
RPNNNTRKRI Undeﬁned 49.7 4.32
RPNNNTGKRI Undeﬁned 77.4 4.36
RPSNNTRKRI Undeﬁned 34.4 4.17
RPTNNTRKSI Undeﬁned 16.6 3.75
RPNNNTRKCI Undeﬁned 67.8 4.63
RPNNNTRKSL RS9 B*07 5.4 3.69
311–320g IGPGRAFYAT Undeﬁned 30864.5 5.64 0.815 NS
IGSGRAFYAT Undeﬁned 29119.6 6.56
IGPGRAFYAA Undeﬁned 19736.5 4.48
IGPGIAFYAT Undeﬁned 27013.2 5.91
341–349 TLEQVVKKL Potential 10358.5 5.34 0.824 0.001
ALEQVVKKL Potential 4739.2 4.93
MLEQVVKKL Potential 2643.9 4.99
TLAQVVKKL Potential 1205.9 4.55
TLEQVVEKL Potential 3291.8 5.11
ILEQVVKKL Potential 4295.9 5.35
TLEQVVNKL Potential 3678.9 5.14
TLDKVVKKL Potential 3003.6 4.96
TLGRVAKKL Potential 8819.8 6.03
TLGQVVEKL Potential 677.1 4.45
TLDKVVEKL Potential 431.5 4.36
TLGKVVKKL Potential 4549.2 4.85
Nef
68–76 FPVRPQVPL B*0702 8.6 3.83 0.9766 0.0015
FSVRPQVPL Potential 2500.2 4.85
FPARPQVPL Potential 5.2 3.66
SPVRPQVPL Potential 8.4 3.67
FPIRPQVPL Potential 7.9 3.62
77–85 RPMTWKGAL Potential 2.9 3.85 0.0733 NS
RPMTWKAAL Potential 2.7 3.86
RPMTYKGAL Potential 2.6 3.89
RPMTRKAAL Potential 2.1 3.82
RPMTCKGAL Potential 2.9 3.74
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number of peptide sequences tested at that time point (Fig. 4) (Liu
et al., 2011). Viewing the data in this fashion allowed us to
evaluate the overall breadth and efﬁciency of memory responses
during progressive HIV-1 infection. The total percent of epitope
variants inducing HIV-1-speciﬁc memory T cell responses peaked
early post-SC, then declined and remained minimal shortly after
Table 1 (continued )
MHC class I binding
HIV-1 proteina (epitope position) Sequence b HLAc restriction netMHCpand log IC50e Correlation coefﬁcient p value
RPMTYKAAL B*0702 2.4 4.04
RPITYKAAL Potential 3.2 3.87
128–137 TPGPGTRYPL Undeﬁned 20.3 3.57 0.9076 o0.0001
TPGPGIRFPL Undeﬁned 43.7 3.4
TPGPGIRYPL B7 34.8 3.78
TPGPGIRYPV Undeﬁned 142.3 3.74
TPGPGIRFPI Undeﬁned 150.3 3.77
TSGPGTRFPL Undeﬁned 5462.9 4.85
IPGPGRHPL Undeﬁned 16.8 3.51
TPGPGVRYPL B7 supertype 30.3 3.64
TPGPGPRYPL Undeﬁned 30.3 3.77
TPGPGTRFPL Undeﬁned 23.7 3.46
TPGPGPRFPL Undeﬁned 35.9 3.66
TPGPGIRYPM Undeﬁned 36.1 3.5
TPGPGPRYPV Undeﬁned 117.7 3.82
TPGPGPRYPM Undeﬁned 33.2 3.57
TKGPGIRFPL Undeﬁned 12856.5 5.41
136–145 PLTFGWCFKLh Undeﬁned 4173.8 6.48 0.00 NS
PLTLGWCFKL Undeﬁned 5994.1 6.10
PITFGWCFKL Undeﬁned 16105.3 6.35
PVTFGWCFKL Undeﬁned 19876.4 6.48
PLCFGWCFKL Undeﬁned 3451.6 4.86
PVCFGWCFKL Undeﬁned 18878.7 5.4
PMCFGWCFKL Undeﬁned 2898.1 5.3
PLCFGWCFKP Undeﬁned 36444.9 5.34
180–189 VLVWRFDSSL Undeﬁned 212.2 4.4 0.8315 0.0042
VLVWKFDSSL Undeﬁned 179.6 4.37
VLVWKSDSSL Undeﬁned 401.3 4.76
VLVWKFDSNL Undeﬁned 197.4 4.31
VLVWKFDSKL Undeﬁned 330.1 4.82
VLVWKFDSRL Undeﬁned 290.0 4.44
VLVWKFDSHL Undeﬁned 154.6 4.22
a The following families and their variants were used in memory and priming T cell assays: SLFNTVATL, TLNAWVKVV, RMYSPTSIL, TLEQVVKKL, FPVRPQVPL,
RPMTWKGAL, and TPGPGTRYPL. The following families and their variants were used in memory T cell assays only: SPRTLNAWV, IGPGRAFYAT, PLTFGWCFKL, and
VLVWRFDSSL (except VLVWKFDSNL). All variants of the RPNNTRKSI Env family were used in memory T cell assays except the followings: RSNNNTRKSI, RPNNNTGKRI,
RPSNNTRKRI, RPNNNTRKCI. All these variants in addition to RPNNNTRKSL were used in priming assays except RPNNNTRKCI.
b These sequence variants of HIV-1 epitopes are listed in order of time of appearance during the course of infection.
c These are known or potential MHC class I epitopes deﬁned by the HIV sequence database as HLA A*0201 or B*0702. A potential epitope is a single peptide having
C-terminal anchor residues and internal anchors matching one or more motifs associated with the submitted HLA, but are not found in the HIV sequence database.
d This is the IC50 (nM) prediction binding score of peptides under investigation. Strong binders have an IC50 threshold of 50 and weak binders have a threshold
of 500.
e LogIC50 is used to refer to the experimental (in vitro) binding of peptides to HLA A*0201 or B*0702. The followings are the binding afﬁnity based on the log IC50: high
afﬁnityo3.7, mediumo4.7, lowo5.5, and no afﬁnityo6.0.
f NS: Pearson correlation, between predicted and experimental MHC binding, is not signiﬁcant, p value40.05.
g These autologous sequences are variants of the known, optimal HLA A*0201-restricted Env gp160311–320 epitope (RGPGRAFVTI), but are not deﬁned as potential or
known epitopes based on the Los Alamos HIV Database.
g LTFGWCFKL can bind all ﬁve HLA-A2 supertypes alleles: A*0201, A*0202, A*0203, A*0206 and A*6802.
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Fig. 3. Proportion of HIV-1 epitope variants exhibiting differential MHC class I afﬁnity. Synthetic 9 mer or 10 mer HIV-1 peptides representing autologous contemporaneous
variants of the study participant were synthesized and evaluated for binding to soluble HLA A*0201 or B*0702 molecules by ﬂuorescence polarization (FP)-based assay to
determine the log IC50 for each variant. Variants were separated into three binding categories based on experimental log IC50 values: high afﬁnity (o3.7), medium afﬁnity
(3.7–4.7), and low afﬁnity (44.7). The longitudinal changes in the proportion of these variants within Gag, Env, and Nef variants, as well as in all epitopes evaluated, are
shown for early post-SC, late-post-SC, and early cART time points. SC, seroconversion.
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establishment of the viral set point. This early total T cell response
was reﬂected in speciﬁc targeting of Gag, Env, and Nef peptide
variant sequences (Fig. 4A–C). Overall, we observed a tri-modal
pattern in the breadth of T cell memory (Fig. 4D). Following this
early peak in T cell reactivity, there was a decline in CTL responses
to all three HIV-1 proteins. This pattern of immune reactivity was
associated with an early decrease in plasma viral load to 23,092
copies of HIV-1 RNA, followed by relatively steady levels of HIV-1
RNA for 3.0 years. The greatest breadth,i.e., percent positive
memory responses, to Gag, Env and Nef variants was observed at
early cART (Fig. 4A–C). This was associated with a decline in viral
load to less than 200 copies/ml of plasma. During late cART, the
total breadth of memory T cell responses declined for both Gag
(Fig. 4A) and Nef (Fig. 4C) epitope variants. Memory responses to
Env variants, however, remained relatively constant (Fig. 4B).
Interestingly, there was no signiﬁcant difference in the percent
of positive responses induced by variants with high, medium or
low afﬁnity to MHC class I at any time point tested post-SC
(Fig. 4E). Thus, our data suggest that HIV-1 epitope variants with
different MHC class I binding capabilities can induce equally broad
memory T cell responses. Overall, we observed signiﬁcant correla-
tionsbetweenthe frequencyofvariantswithhigh,medium,and low/
noafﬁnityandthepercentageeachof thesecontributedtotheoverall
breadthof theautologousmemoryresponseearlypost-SC(p¼0.003,
r2¼0.601), late post-SC (po0.0001, r2¼0.827), early cART
(po0.0001, r2¼0.815), and at late cART (po0.0001, r2¼0.816).
Our results indicate a typical course of progressive HIV-1 infection
whereby an early increase in anti-HIV-1 CTL activity is associated with
a decrease in HIV-1 viremia. As the untreated virus infection resulted
in inexorable immune dysfunction, T cell reactivity no longer con-
trolled viral replication. Initiation of cART was associated with control
of viral replication and a temporal enhancement of anti-HIV-1
CTL responses that eventually declined to a low level, steady state
(Casazza et al., 2005; Kalams et al., 1999; Rinaldo et al., 2000).
Fig. 4. Viral load and the proportion of positive of HIV-speciﬁc T cell memory responses pre- and post-therapy. Synthetic peptide sequences representing autologous variants
of subject 8 were loaded onto mature autologous DC and used to stimulate cryopreserved autologous PMBC. PBMC were added to wells at a responder-to-stimulator ratio of
10:1. Epitope-speciﬁc T cell responses were measured by IFN-γ ELISPOT assay. Results reported represent mean values of duplicates and expressed as spot forming cells (SFC)/
106 PBMC. The proportion (percent) of positive memory-speciﬁc T cell responses is deﬁned as the number of in vitro T cell responses directed against naturally occurring
peptide sequences in subject 8 per total number of variant sequences tested during the corresponding time multiplied by 100. The proportion (percent) positive of memory T
cell responses (y-axis) is plotted against time in years post-SC (x-axis). The viral load at respective time points during infection is also shown. Viral load (red line) and total
proportion/or percent of positive T cell-speciﬁc memory responses (black line) to Gag (A), Env (B), Nef (C) and total number of peptides tested (D) per tested sequence are
shown against time post-SC. (E) Gag, Env and Nef epitope variants classiﬁed by ﬂuorescence polarization (FP) assay as high, medium or low binding afﬁnity (including those
classiﬁed as low and non-binders by the FP assay) to MHC class I are plotted (x-axis) against the proportion/percent positive memory responses they stimulate as measured
by IFN-γ ELISPOT assay (y-axis). Afﬁnity binding categories are based on the values of log IC50: high afﬁnityo3.7, mediumo4.7, lowo5.5, and no afﬁnityo6.0. SC,
seroconversion; SFC, spot-forming cells.
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The changing magnitude of T cell memory responses targeting
autologous HIV-1 variant sequences
We next assessed the longitudinal change in T cell responses to
autologous Gag, Env, and Nef epitope variants (Table 1). Mature,
autologous DC were loaded with synthetic peptides representing
contemporaneous Gag, Env, and Nef CTL epitope variants and
these peptides were used to stimulate PBMC in IFN-γ ELISPOT.
Because sequencing data were not available for late cART time
points, we used epitope variants reﬂecting circulating sequences
during early cART in the late cART T cell memory assays. T cell
memory responses to Gag families (SLFNTVATL, SPRTLNAW,
TLNAWVKVV and RMYSPTSIL) ranged from 0 to 800 SFC/106 PBMC
(Fig. 5). Early post-SC we observed modest IFN-γ recall responses
to 3 out of the 4 Gag families (SLFNTVATL, SPRTLNAW and
TLNAWVKVV) (Fig. 5A–C). These T cell responses decreased to
low or undetectable levels late post-SC. More robust memory T cell
responses were observed early following cART against the tested
contemporaneous sequences of the same Gag families. In contrast,
there were little or no memory responses to the RMYSPTSIL
variants early post-SC, which moderately increased late post-SC
(Fig. 5D). SLFNTVATL, TLNAWVKVV (known HLA A*0201 epitopes),
and SPRTLNAWV (known HLA-B*0702 epitope) naturally circu-
lated at all time points. The magnitude of T cell responses to these
variants consistently increased early following cART. These
responses were either reduced or completely lost during late
therapy. T cell responses targeting Gag variants circulating at early
cART were statistically signiﬁcant and higher than responses
targeting variants circulating at early and late post-SC, and during
late cART (Fig. 5E).
We observe strong T cell responses targeting the tested variants
of the RPNNNTRKSI evolving late post-SC (Fig. 6A). RPNNNTRKSI, a
known HLA-B*0702 lingering throughout the course of infection,
did not induce memory responses early post-SC; however, increas-
ing responses were detected late post-SC and following cART. Low
to no memory responses were produced against the tested
TLEQVVKKL sequences arising late post-SC (Fig. 6B). Variant
sequences of this family of peptides are identiﬁed as potential
Fig. 5. Longitudinal development and changes in magnitude and breadth of Gag-speciﬁc T cell memory responses associated with the emergence of viral variants. As
previously described, synthetic 9 mer or 10 mer HIV-1 peptide sequences representing autologous contemporaneous variants of the study participant were sequenced,
synthesized and loaded into mature autologous DC. DC are used to stimulate cryopreserved autologous PMBC at a responder-to-stimulator ratio of 10:1. Epitope-speciﬁc T
cell responses are measured by IFN-γ ELISPOT assay. Gag-speciﬁc IFN-γ responses (y-axis) to contemporaneous variants sequences of (A) SLFNTVATL (p17 77–85),
(B) SPRTLNAWV (p24 16–24), (C) TLNAVWVKVV (p24 19–27), and (D) RMYSPTSIL (p24 143–151) are shown across time. Blue histograms, early variants emerging at 0–2.8
years post-SC and tested with autologous PBMC; green histograms, late variants emerging at 3.3–7.8 years post-SC and tested with autologous PBMC; red histograms, early
cART variants emerging at 8.3–10.1 years post-SC and tested with autologous PBMC. Epitope-speciﬁc T cell responses labeled as late cART represent sequences evolving at
early cART and assumed to linger through (410.1 years post-SC). (E) Total Gag-speciﬁc memory responses emerging at early (0–3 years post-SC), late (3.25–7.75 years post-
SC), early cART (8–10.25 years post-SC) and late cART (410.5 years post-SC). SC, seroconversion, SFC, spot-forming cells. Standard error bars are shown when applicable.
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epitopes by the Los Alamos database (Table 1). As observed with Gag
variants, therapy maintained T cell responses to early and late variants
with clear increase in T cell reactivity as tested by IFN-γ ELISPOT assay.
A statistically signiﬁcant mean difference was observed between T cell
responses targeting early and late Env variants of RPNNNTRKSI and
TLEQVVKKL families of peptides (Fig. 6C).
Variants of Nef families (FPVRPQVPL, RPMTWKGAL, TPGPGTRYPL,
PLTFGWCFKL and VLVWRFDSSL) were next tested for their ability to
Fig. 6. Longitudinal development and changes in magnitude and breadth of Env-speciﬁc T cell memory responses targeting naturally evolving viral variants. As previously
described for Gag, synthetic Env peptide sequences representing contemporaneous variants of the study participant were sequenced, synthesized and loaded into mature
autologous DC. Similarly, DC are used to stimulate cryopreserved autologous PMBC at a responder-to-stimulator ratio of 10:1. Epitope-speciﬁc T cell responses are measured
by IFN-γ ELISPOT assay. Env-speciﬁc IFN-γ responses (y-axis) to contemporaneous (A) RPNNNTRKSI (298–307) and (B) TLEQVVKKL (341–349) variants are shown across time.
Blue histograms, early variants emerging at 0–2.8 years post-SC and tested with autologous PBMC; green histograms, late variants emerging at 3.3–7.8 years post-SC and
tested with autologous PBMC; red histograms, early cART variants emerging at 8.3–10.1 years post-SC and tested with autologous PBMC. Epitope-speciﬁc T cell responses
labeled as late cART represent sequences evolving at early cART and assumed to linger through (410.1 years post-SC). (C) Pairwise-comparison between Env-speciﬁc T cell
memory responses emerging at early (0–2.8 years post-SC), late (3.3–7.8 years post-SC), early cART (8.3–10.1 years post-SC) and late cART (410.1 years post-SC). SC,
seroconversion, SFC, spot-forming cells. Standard error bars are shown when applicable.
Fig. 7. Longitudinal development and changes in magnitude and breadth of Nef-speciﬁc T cell memory responses associated with the emergence of viral variants.
As previously described for Gag and Env, synthetic contemporaneous variants of Nef peptide sequences were loaded into mature autologous DC isolated from our study
participant and epitope-speciﬁc T cell responses are measured by IFN-γ ELISPOT assay. Nef-speciﬁc IFN-γ responses (y-axis) to contemporaneous variants sequences of
(A) FPVRPQVPL (68–76), (B) RPMTWKGAL (77–85), (C) TPGPGTRYPL (128–137), and (D) PLTFGWCFKL (136–145), and (E) VLVWRFDSSL (180–189) are shown across time. Blue
histograms, early variants emerging at 0–2.8 years post-SC and tested with autologous PBMC; green histograms, late variants emerging at 3.3–7.8 years post-SC and tested
with autologous PBMC; red histograms, early cART variants emerging at 8.3–10.1 years post-SC and tested with autologous PBMC. Epitope-speciﬁc T cell responses labeled as
late cART represent sequences evolving at early cART and assumed to linger through (410.1 years post-SC). (F) Pairwise-comparison between Nef-speciﬁc memory
responses emerging at early (0–3 years post-SC), late (3.25–7.75 years post-SC), early cART (8–10.25 years post-SC) and late cART (410.5 years post-SC) time points.
SC, seroconversion, SFC, spot-forming cells. Standard error bars are shown when applicable.
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induce T cell memory responses (Fig. 7). FPVRPQVPL, a founder
sequence and a known B*0702 epitope (Table 1), was frequently
present during the course of infection and stimulated low memory
responses at all studied time points with a moderate increase
following the administration of cART (Fig. 7A). The founder
sequences of the RPMTWKGAL family induced speciﬁc-memory
responses in vitro. The switch observed in the dominant form of
the estimated founder sequence RPMTWKGAL to become
RPMTWKAAL was associated with maintenance of the ability of the
latter to induce memory responses until early cART (Fig. 7B). These
responses were lost during late therapy. RPMTWKAAL is also
identiﬁed as a known B*0702 epitope whereas the remaining
variants are identiﬁed as potential epitopes (Table 1).
Peptide variants of the TPGPTRYPL, PLTFGWCFKL and
VLVWRFDSSL families were phylogenetically similar in that multiple
variants existed concurrently (Fig. S1). The majority of TPGPGTRYPL
variants arising early post-SC induced low to moderate memory
responses (Fig. 7C); responses to the variants lingering to late time
points were reduced. Early and late cART time points were associated
with maintenance of moderate responses to contemporaneous
sequences and loss of response to one of the studied founder
sequences (TPGPGTRYPL). Responses to TPGPGIRYPL, a HLA B*07
epitope (Table 1), were reduced with time whereas the TPGPGVRYPL
variant, a B*07 supertype, was not able to stimulate memory
responses early post-SC. LTFGWCFKL (Table 1) is reported by the
Los Alamos database to bind all ﬁve HLA-A2 supertype alleles:
A*0201, A*0202, A*0203, A*0206 and A*6802. Memory responses
to two 10mers containing variants of LTFGWCFKL (PLCFGWCFKL and
PMCFGWCFKL) induced no-to-low memory responses; the latter
recovered during therapy with eventual loss at late cART time points
(Fig. 7D). VLVWKFDSKL and VLVWKFDSRL emerged at late and early
cART time points respectively and were the only variants in this
family to induce moderate to high memory responses (Fig. 7E).
Pairwise comparisons showed statistical differences in mean
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Fig. 8. In vitro primary T cell responses induced in HIV-positive subject to naturally evolving viral variant sequences in an entirely autologous system. Mature DC isolated
from subject 8 and HLA-matched HIV-1 naïve donors were loaded with 10 mg/ml of subject 8 variant sequences detected during the course of infection. DC were used to
prime autologous PBMC isolated from healthy donors and from the study participant prior to seroconversion. The magnitude of T cell primary responses is tested by IFN-γ
ELISPOT assay. In vitro primary T cell responses (y-axis) of PBMC isolated prior to seroconversion to (A) Gag (SLFNTVATL, TLNAWVKVV, RMYSPTSIL), (B) Env (TLEQVVKKL,
RPNNNTRRSI) and (C) Nef (FPVRPQVPL, RPMTWKGAL, TPGPGTRYPL) viral sequences emerging during early (blue histograms), late (green histograms) and/or cART (red
histograms) time points are shown. The mean values 7SD of SFC/106 PBMC to BMLF1 control peptides are 22177660 (data not shown). (D) Proportion of positive primary T
cell responses (y-axis) to contemporaneous viral sequences of Gag, Env and Nef (x-axis) is deﬁned as the number of peptide variants tested within each protein and inducing
a positive IFN-γ response per total number of variants tested. SC, seroconversion; SFC, spot-forming cells.
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memory responses between early and early cART time points as well
as between late and early ART time points (Fig. 7F).
We evaluated the impact of MHC class I binding afﬁnity on the
magnitude of memory T cell responses during the course of
infection (Fig. S2). Our data show that Gag, Env and Nef peptide
variants with high or medium afﬁnity induce similar responses
early post-SC while low binders as classiﬁed by the FP-assay
induce statistically signiﬁcant higher responses as compared to
high binders (Fig. S2A). Later during infection (i.e., late, early cART,
and late cART), variants with high, medium and low binding
afﬁnity stimulated similar IFN-γ responses (Fig. S2B-D).
Being a known or potential HLA-A*0201 or HLA-B*0702, the
magnitude of T cell responses elicited by the tested peptide
variants with high and medium binding afﬁnity was generally
similar at different time point post-SC. Low afﬁnity binders of Gag,
Env and Nef variants tested in vitro variably induced T cell
responses with a clear increasing magnitudes following cART.
Broad and high magnitude primary T cell responses to naturally
evolving variants in HIV-1-positive and healthy donors
We have previously demonstrated the ability of mature
monocyte-derived DC from HIV-1-naïve donors to induce broadly
reactive primary CD8þ T cell responses (Colleton et al., 2009).
Little is known about the ability to prime anti-HIV T cell immunity
speciﬁc for variants that evolved during natural infection. Thus, we
next determined the capacity of DC isolated from subject 8 during
cART to prime autologous pre-SC T cells. Autologous DC matured
with CD40-L and IFN-γ (Fan et al., 2007; Huang et al., 2008) were
loaded with Gag (Fig. 8A), Env (Fig. 8B) and Nef (Fig. 8C) peptide
sequences that emerged at early, late, or cART time points post-SC.
These DC were then used in a 21-day in vitro priming assay. The
magnitude of primary T cell responses was tested in an IFN-γ
ELISPOT assay.
Of the 59 peptides tested, HIV-naïve, pre-SC T cells were
primed to 9/15 (60%) Gag, 10/17 (58.8%) Env, and 13/27 (48.4%)
Nef variants. Among these 32 sequences eliciting primary
responses, moderate (4¼100 SFC) to strong (4¼500SFC) pri-
mary IFN-γ responses were noted to known HLA-A*0201 or HLA-
B*0702 epitopes SLYNTVATL (p17), naturally evolving at late time
points; TLNAWVKVV (p24) identiﬁed as a founder sequence;
FPVRPQVPL (Nef), a founder sequence; TPGPGVRYPL emerging
early post-SC and TPGPGIRYPL (Env), a founder sequence (Table 1).
The peptide families containing SLYNTVATL, TLNAWVKVV and
FPVRPQVPL, harbor variant sequences with potential CTL epitopes
(Table 1). Variants of three out of the ﬁve remaining families of
peptides tested in our priming model: i.e., RMYSPTSIL (Gag),
TLEQVVKKL (Env), and RPMTWKGAL (Nef) are also deﬁned as
potential MHC class I-restricted epitopes (Table 1). In summary, a
total of 16 out of 32 variants induced strong primary responses
(4500 SFC) (Fig. 8).
To determine the breadth of primary T cell responses, the
proportion of variants inducing positive primary responses was
deﬁned as the number of variant sequences inducing a positive
primary T cell response/total number of variants tested within a
respective family. The proportion of variants that stimulated
primary responses was not dependent on the HIV-1 protein from
which these variants were derived, as we observed no signiﬁcant
differences between primary responses targeting Gag, Env, and Nef
peptide variants (Fig. 8D). When combined, variants of Gag, Env
and Nef with low binding afﬁnity induced primary T cell responses
with comparable breadth and magnitude as variants with high or
medium afﬁnity (Fig. S3).
Taken together, our results indicate that substantial primary T
cell responses are induced by our model to a diverse number of
HIV-1 peptide variants of the virus proteome. Being a known,
potential, or undeﬁned HLA-matched epitope, with high, medium,
or low binding afﬁnity did not inﬂuence the ability of our priming
model to stimulate robust T cell responses in an entirely auto-
logous system.
To evaluate the person-to-person variation in T cell priming
capacity of the HIV-1 variant peptides from subject 8, we used PBMC
from 2 healthy, HIV-1 naïve, HLA matched (HLA-A2/B7) donors.
SLYNTVATL (Gag p17), TLNAWVKVV (Gag p24), FPVRPQVPL (Nef) and
their naturally evolving variants were tested. T cells from donor 0038
responded to all SLYNTVATL (6/6) variants, 4 out of 5 TLNAWVKVV
variants and all (5/5) FPVRPQVPL variants. Similarly, donor 2256
responded to all variants except one within the FL9 family (Fig. 9).
We found no signiﬁcant difference between the magnitude of the
IFN-γ primary responses stimulated by peptide variants of our HIV-
positive study participant and those of HIV-naïve volunteers.
Discussion
We report the evolution of HIV-1 in an infected subject across
time and the impact of HIV-1 variants and respective MHC class I
binding afﬁnities on the breadth and the magnitude of T cell
memory responses. Our data show that with higher sequence
diversity, the proportion of T cell memory responses targeting
contemporaneous variant peptide sequences of the proteome
increases. It has been previously reported that the continuous
presence of antigen is important for the maintenance of CTL
responses (Shin et al., 2007; Wherry et al., 2004). Moreover, Liu
et al. (2011) recently reported in cART-naïve setting that a balance
is likely needed between the presence of antigen and prolonged
antigen stimulation. Along similar lines, our results suggest the
dynamic ability of evolving viral sequences to continuously exist
and stimulate speciﬁc T cell responses.
T cell responses directed against individual known or optimal
peptide sequences (Gag: SLFNTVATL, SLYNTVATL, TLNAWVKVV;
Env: RPNNTRKSI; Nef: FPVRPQVPL, RPMTYKAAL, TPGPGVRYPL)
evolving early during infection were temporally enhanced during
early cART, followed by a decline or complete loss in late cART.
We have previously observed such a temporal effect on CTL
activity to consensus HIV-1 epitopes (Rinaldo et al., 2000). This
observation was not limited to optimal epitopes as similar trends
were observed against potential epitopes and previously unde-
ﬁned epitopes (Table 1). Moreover, our results show a clear
correlation between the frequency of autologous peptide variants
during infection and the breadth but not the magnitude of these
responses. These results are in agreement with the lack of
correlation between the magnitude of CTL responses and HLA
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Fig. 9. In vitro primary T cell responses induced in healthy HIV-1 negative donors
to naturally evolving HIV-1 viral variants. Mature DC isolated from HIV-1 naïve
donors HLA A*0201 matched with subject 8 were loaded with naturally evolving
variants detected during his course of infection, and used to prime autologous
PBMC. The magnitude of T cell primary responses was tested by IFN-γ ELISPOT.
SLFNTVATL, TLNAWVKVV and FPVRPQVPL variants (x-axis) of subject 8 were used
in our priming model to stimulate primary T cell responses (y-axis) of PBMC
derived from donor 0038 and donor 2256. SFC, spot-forming cells.
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binding afﬁnity (Bihl et al., 2006; Tenzer et al., 2009). Importantly,
our data indicate that the breadth of T cell responses targeting
contemporaneous epitopes representing different parts of the
HIV-1 proteome is comparable early post-SC, late post-SC, or
during cART regardless of the experimental binding capacity to
the cognate MHC class I molecules.
Even though a small repertoire of Gag, Env, and Nef peptide
families was used in this study, all of the tested autologous HIV-1
epitope variants maintained a functionally detectable or predicted
level of binding to MHC class I. Further assessment of peptide
binding to MHC and its relation to T cell memory responses will
need to categorize percent recognized (T cell reactive) and percent
non-recognized (T cell non-reactive) variants in relation to viral
peptides exhibiting a broader range of MHC binding. This is
especially important since a number of mechanisms such as T cell
escape, change in the antigen load and T cell exhaustions (Turnbull
et al., 2009) could lead to decline of T cell responses during HIV-1
infection.
The minimum impact of MHC class I afﬁnity observed in this
study suggests that the breadth of recognition of peptide variants
could be partially due to the promiscuity of TCR (Buseyne and
Riviere, 2001). Limited TCR diversity within cognate clonotypes
has been suggested to facilitate immune escape through loss of
CD8þ T cell recognition (Davenportet al., 2007; Price et al., 2004).
Recently, dominant HIV-speciﬁc CD8þ T cell clonotypes were
found to persist in vivo for long periods of time while being able
to cross-recognize naturally occurring epitope variants (van Bockel
et al., 2011). A high clonotypic turnover of HIV-speciﬁc CD8þ T
cells was described following intiation of HAART or upon appear-
ance of viral mutations; moreover, authors showed new cognate
clonotypes during decreased or limited antigen load (Janbazian
et al., 2012). These clonotypes became dominant and were
characterized by high functional capabilities. While we do not
have data on the evolution of HIV-speciﬁc CD8þ T cell repertoire
clonal composition in our participant or the functional proﬁles of
the detected T cell responses, we believe that we might be dealing
with a similar reconstitution post cART.
In our study, T cell responses were detected to 81% (63/78) of
the total tested variants in the study participant, 8 of which are
classiﬁed as optimal epitopes and 29 as potential epitopes as
described by the Los Alamos HIV database. Post-STEP trial empha-
sis has been on the beneﬁt of maximizing the T cell coverage,
i.e., breadth, of the contemporaneous forms of the virus (McElrath
et al., 2008). Even though correlation between the breadth of the
CTL responses and the containment of virus in vivo has been
controversial (Addo et al., 2003; Frahm et al., 2004; Liu et al.,
2007), we and others (Rolland et al., 2008) believe that the
probability of inducing protective anti-HIV CTL responses is likely
to be enhanced by broader range of immunogenic epitopes
presented professionally by APC. We acknowledge the limitation
of monitoring viral sequences longitudinally from one subject in
addition to the limited repertoire of peptide epitopes tested in this
study; hence, we might have missed important motifs implicated
in better MHC binding and consequently effective T cell responses.
The genetic diversity of HIV-1 and the propensity of the virus to
undergo escape mutations are major hurdles for long-term
immune control of HIV-1. With the current lack of a preventive
HIV-1 vaccine, alternatives are needed to improve the quality of
the immune responses targeting the virus and thus reducing its
transmission. It has been proposed that the magnitude and the
quality of the memory T cell pool is affected by the activation of
naïve CD8þ T cells by licensed DC and that excessive antigenic
stimulation leads to terminal differentiation and impairment of
these memory CD8þ T cells (Zehnet al., 2009). We have previously
demonstrated the potent capability of mature monocyte-derived
DC from uninfected donors to induce a broad spectrum of primary
CD8þ T cell responses targeting epitopes in Gag, Env, and Nef
(Colleton et al., 2009). Our in vitromodel was successful at priming
HIV-naive CD8þ T cells to consensus HIV-1 epitopes as well as
other viral peptides in vitro. A series of events have been described
to be involved in triggering the stimulation of the TCR on naïve
CD8þ T cells. The TCR and signaling by co-stimulatory and
cytokine receptors drive the magnitude and the quality of the
response (Prlicet al., 2007).
Consequently, we have proposed the enhancement of the primary
responses of naïve CD8þ T cells to a broad array of HIV-1 epitopes
while patients are on ART for better control of viral replication and
disease (Rinaldo, 2009). In this study, we conﬁrm the ability of our
in vitro model to stimulate autologous pre-SC naïve T cells from our
study participant against 54% (32/59) of tested autologous peptide
variants that emerged at different stages pre- and post-therapy.
Moderate to strong primary responses were induced to variants from
a variety of known and potential Gag, Env, and Nef epitopes in an
entirely autologous system. Moreover, the time post-SC at which the
epitope variant evolved did not affect the magnitude of the primary T
cell responses. The elicited primary responses were not exclusive to
already deﬁned known and potential epitopes. A number of variant
sequences of Env and Nef were not deﬁned by the Los Alamos HIV
database, yet had predicted and experimental HLA-binding afﬁnity.
Taken together, this in vitro priming model stimulates primary T cell
responses regardless of the nature (i.e., known or undeﬁned), origin
(HIV-1 protein), and MHC binding afﬁnity (high, medium or low
binders) of the tested HIV-1 epitope variants. Even though cART has
been successful at controlling HIV-1 viral load, immune recovery is
still a challenge (Corbeau and Reynes, 2011). We propose by-passing
this obstacle by using a DC immunotherapy aimed at inducing a
primary T cell response from naïve precursors in subjects on cART.
This is especially important due to de novo priming of new
clonotypes occurring during persistent viral infections (Vezys et al.,
2006) and vaccination (Rosario et al., 2010).
As a proof-of-concept, we demonstrated the ability of our
priming model to robustly prime autologous T cells derived from
2 HIV-1 naïve volunteers to a broad range of Gag and Nef peptide
variants derived from the study subject. 25% and 75% of these
peptides were known and potential HLA A*0201 and HLA-B*0702
epitopes, respectively, as deﬁned by the Los Alamos HIV Immu-
nology Database. Our model was able to generate primary
responses targeting immunodominant (SL9, FL9) and subdominant
(TV9) epitopes and their variants. It is well established that
immunodominant HIV-speciﬁc CTL responses can exert selection
pressure on the virus during primary infection (Allen et al., 2000;
Barouch et al., 2003). Even though subdominant epitopes stimu-
late T cells less frequently, the elicited responses are protective
(Bihl et al., 2006; Borrow et al., 1997; Draenert et al., 2004; Jones
et al., 2004). Our model does not differentiate between viral
sequences based on immunodominance. A signiﬁcant difference
was observed between the magnitude of these in vitro primary
responses generated by cells of our normal donors. The reason for
failure to detect similar in vitro primary responses between the
2 normal donors could be due to differences in T cell precursor
frequencies. Importantly, we found no difference between the
magnitudes of primary responses of our 2 healthy donors target-
ing HIV-1 evolving variant sequences derived from our study
participant when compared to those targeting the same variants
using pre-SC or HIV-naïve cells from our study participant. These
ﬁndings show that, prior to HIV infection and immune dysfunc-
tion, the naïve T cell repertoire found within subject 8 was capable
of recognizing and responding to primary stimulation against the
variants that evolved after seroconversion. The mutations that
evolved after infection, particularly those that appeared late post-
SC, may have evolved to speciﬁcally evade T cell recognition. This
would have implications in immunotherapy approaches, which aim
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to induce primary responses against these “late evolving” viral
variants. Indeed, our induction of primary responses against these
variants prior to SC supports that immunotherapies implemented
during cART could be successful at inducing CTL speciﬁc for auto-
logous viral variants. While we acknowledge the need for further
exploration of the speciﬁc TCR clonotypic repertoire associated with
emerging viral variants and its ability to control HIV-1 replication, we
believe that the present work highlight the importance of primary
responses against HIV-1 variants in a continuous environment
of competition between HIV-1 and virus-speciﬁc T cell responses.
A recent study on mutations within the KK10 epitope at different
positions suggest the capacity of KK10-speciﬁc CD8þ T cell response
to attract an array of cross-reactive clonotypes from existing reper-
toire to control HIV-1 infection (Ladell et al., 2013). We believe that
the described primary responses are similarly capable of assembling
T cell clonotypes to control the ability of emerging viral variants to
affect TCR recognition.
With the clonal exhaustion of CD8þ T cells as a result of chronic
HIV-1 infection and the pressure exerted on memory T cells to
recognize wild-type and mutant variants, we and others
(Appayet al., 2008) believe that an effective T cell response would
have to generate a long lasting protection environment. Engineer-
ing DC to prime naïve T cells to immune escape variants (Rinaldo,
2009) could be a potential approach to overcome the challenges
faced by circulating memory T cells.
Materials and methods
Study participants
Human subject approval was obtained for this study from the
institutional review board of the University of Pittsburgh. The parti-
cipant in this study (subject 8) is enrolled in the Multicenter AIDS
Cohort Study (MACS), a natural history study of HIV-1 infection in men
who have sex with men (Detels et al., 2012; Kaslow et al., 1987).
The subject's MHC class I alleles as determined by high resolution PCR
genotyping (Tissue Typing Laboratory, University of PittsburghMedical
Center) are HLA-A*0201, A*2402, B*0702, B*4001, C*0304, and
C*00702. Subject 8 was HIV-1 seronegative upon enrollment in the
MACS in November, 1984, and seroconverted to HIV-1 between
October 1987 and May 1988. HIV-1 seropositivity was conﬁrmed by
a positive enzyme-linked immunosorbent assay (ELISA) for the pre-
sence of HIV-1 p24 and aWestern blot with bands corresponding to at
least 2 of either Gag, Pol, and Env (Kaslow et al., 1987). Blood
specimens, and epidemiologic and clinical data were obtained at
semiannual visits (Shankarappa et al., 1999). Participant 8 progressed
to AIDS as deﬁned by the CDC (o200 CD4þ T cells/mm3) 6.2 years
post-SC. cART was initiated on July, 1996 at 8.4 years post-SC. This
treatment regimen, consisting of Retrovir (zidovidine azidothymidine,
GlaxoSmithKline), Epivir (lamiduvidine 3TC, GlaxoSmithKline) and
Invirase (saquinovir mesylate, Roche), was administered for 1 year.
At 9.4 years post-SC, Viracept (nelﬁnavir mesylate, Agouron), Sustiva
(efavirenz, Bristol-Meyers Squibb) and Ziagen (abacavir sulfate, Glax-
oSmithKline) replaced the previous regimen. This treatment was
ﬁnally replaced with Atrilpa (efavirenz/emtricitabine/tenofovir,
Bristol-Meyers Squibb) at 20.5 years post-SC and was maintained for
the period of study. Blood was also obtained from 2 anonymous,
healthy HIV-1 negative donors (Central Blood Bank, Pittsburgh, PA)
who were typed as HLA-A2/B7 by ﬂow cytometry for use in the T cell
priming study.
Clinical and virologic characteristics
At each clinic visit pre- or post-SC and during cART, plasma
samples and peripheral blood mononuclear cells (PBMC) were
collected and stored at 80 1C and 1401C, respectively. Plasma
samples and PBMC were used to determine HIV-1 load and CD4þ
and CD8þ T cell counts, respectively. T cell phenotypes were
determined by ﬂow cytometry as previously described (Giorgi
et al., 1990; Schenker et al., 1993). For HIV-1 plasma viremia, RNA
was extracted from plasma using a COBAS© Ampliprep Instrument
(Roche Diagnostics, Indianapolis, IN) and ampliﬁed by RT-PCR on a
COBAS© Taqman© 48 Analyzer (Roche Diagnostics) using the
COBAS© Ampliprep/COBAS© Taqman HIV-1 Test. This assay is
capable of detecting from 20 to 106 HIV-1 RNA copies/ml of
plasma. Negative, low positive and high positive controls were
used in each RNA extraction and RT-PCR assay as per manufac-
turer's instructions.
Sequencing and phylogenetic analysis
env C2-V5 sequences were reported previously (Shankarappa
et al., 1999). gag and nef sequences were obtained using the
procedures and primers as previously described (Liu et al., 2006;
Malhotra et al., 2007; Shriner et al., 2004). Brieﬂy, viral sequences
were derived from 12, 16, and 9 time points for gag-p17 and -p24,
env-gp120, and nef, respectively. Sequences spanned 8 years of
untreated HIV-1 infection and included at least one post-cART
time point. Viral sequencing was not performed during late cART
due to inability to detect viral RNA in plasma.
Sequences bearing open reading frames (90% of all sequences
determined) were ﬁrst aligned with the Pileup program in the
GCG suite (Genetics Computer Group, Madison, WI) and then
manually edited (Liu et al., 2006, 2007). Both viral divergence from
the founder strain and viral diversity were estimated at each time
point. To estimate viral diversity, we determined the mean and
standard deviation for pairwise nucleic acid distances between all
sequences obtained at each time point. To estimate viral diver-
gence, we compared sequences from each visit to a founder
sequence that was approximated as the consensus sequence found
at the initial virus-positive time point. The mean and standard
deviation for all pairwise comparisons were then calculated.
Synthetic peptides
Peptide sequences representing autologous Gag, Env, and Nef
MHC class I-associated variants evolving in our study participant
during infection were synthesized (SynBioSci., Livermore, CA) and
used in T cell priming and memory T cell functional assays.
Epstein–Barr virus (EBV) BMLF1280–288 (GL9, GLCTLVAML) (pro-
vided by the NIH AIDS Research Program) was used as a control
peptide sequence in the functional assays. The Los Alamos HIV
Molecular Immunology Database was referred to for deﬁning MHC
Class I epitopes based on being known as optimal epitopes or
based on afﬁnity, T cell receptor usage, computational epitope
prediction or functional studies. For ease of interpretation, the
naturally evolving peptide sequences of subject 8 are referred to in
order of their detection post-SC. Consequently, we deﬁned early
post-SC (0–2.8 years post-SC), late post-SC (3.25–7.8 years), early
cART (8.3–10.1 years) and late cART (12.4–13.1 or 412.4 years)
time points.
In silico and in vitro analysis of peptide binding afﬁnity
HLA peptide binding predictions of the sequences under investi-
gation were scored using the netMHCpan 2.4 server (www.cbs.dtu.
dk/services/NetMHCpan) (Hoof et al., 2009; Nielsen et al., 2007).
In silico (predicted) IC50 values were computed with binding afﬁnity
of peptides for MHC class I. Strong binders were assigned as having
an IC50 threshold of 50 nM and weak binders as having a threshold of
500 nM. A ﬂuorescence polarization (FP)-based assay was used to
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experimentally screen and identify high afﬁnity binding peptides to
HLA molecules (Pure Protein LLC, Oklahoma City, OK). Brieﬂy, the
assay utilizes ﬂuorescently labeled control peptides and recombinant
soluble HLA-A*0201 and B*0702molecules to test for the competitive
binding between a labeled reference peptide and the peptide or the
peptide mix being investigated. The binding afﬁnity of the compe-
titor peptide is expressed as the concentration inhibiting 50% (IC50) of
the binding of the labeled peptide (Buchli et al., 2005). The followings
are the binding afﬁnity categories based on the log IC50: high
afﬁnityo3.7, mediumo4.7, lowo5.5, and no afﬁnityo6.0 (Buchli
et al., 2005).
Generation of dendritic cells (DC)
Monocyte-derived DC were generated from subject 8 and two
healthy HIV-1 negative adults as previously described (Colleton
et al., 2009) with minor modiﬁcations. Brieﬂy, CD14þ monocytes
were positively selected using anti-CD14 monoclonal antibody
(mAb) coated magnetic beads (StemCell Technologies, Vancouver,
Canada) or Percoll density separation (Sigma-Aldrich, Saint Louis,
MO). DC were generated by culture of the puriﬁed monocytes with
1000 U/ml recombinant GM-CSF (Bayer Healthcare, Montville, NJ)
and 1000 U/ml recombinant IL-4 (R&D Systems, Minneapolis, MN).
On day 5, immature DC were treated for 48 h with recombinant
CD40L (0.5 mg/ml; Enzo, Farmingdale, New York) for use in
memory T cell assays or CD40L (0.5 mg/ml) and interferon γ (IFN-γ;
1000 U/ml; R&D) for use in priming assays.
In vitro priming
In vitro priming of autologous PBMC was performed as pre-
viously described with minor modiﬁcations (Colleton et al., 2009).
Brieﬂy, DC was derived from PBMC obtained from subject 8 during
virus suppressive cART and the HIV-1 negative, adult volunteers.
Autologous DC matured with CD40L and IFN-γ were incubated
with 10 mg/ml of HIV-1 peptides in IMDM medium (Gemini Bio-
Products, West Sacramento, CA) containing 10% heat-inactivated
fetal calf serum (FCS) (Gemini Bio-Products) for 2 h at 37 1C in a 5%
CO2 atmosphere. The DC were harvested and re-suspended with
autologous PBMC at a responder-to-stimulator (T:DC) ratio of 10:1.
Autologous PBMC from subject 8 were obtained from cryopre-
served cells prior to SC. After 3 days, the co-cultures were fed with
fresh IMDM/10% FCS supplemented with recombinant IL-15
(2.5 ng/ml; PeproTech, Rocky Hill, NJ), IL-2 (50 U/ml; Chiron,
Emeryville, CA) and IL-7 (10 ng/ml; Miltenyi, Auburn, CA). This
was repeated at 2–3 day intervals thereafter for 2 weeks. PBMC
were then re-stimulated with autologous DC loaded with the same
set of peptides as in the primary stimulation at a responder-to-
stimulator (T:DC) ratio of 10:1. These cells were harvested after a
total of 21 days of culture and used in IFN-γ ELISPOT assays.
IFN-γ ELISPOT assay
ELISPOT assays were performed as previously described
(Colleton et al., 2009; Huang et al., 2008). Brieﬂy, 96 well plates
were coated overnight with 1 mg/ml anti-human IFN-γmAb 1-D1K
(Mabtech, Stockholm, Sweden) at 4 1C. DC matured with CD40L
were loaded with 10 mg/ml HIV-1 peptides or control EBV peptide
in IMDM/10% FCS for 2 h at 37 1C. Control wells contained T cells in
the presence of mature DC. Autologous PBMC in IMDM/10% FCS
were added to wells at a responder-to-stimulator ratio of 10:1 and
were incubated for 18 h at 37 1C in a 5% CO2 atmosphere. Follow-
ing incubation, wells were washed with PBS/0.05% Tween-20
(Fisher Scientiﬁc, Pittsburgh, PA) and were treated with biotiny-
lated anti-IFN-γ mAb (1 mg/ml; Mabtech, Stockholm, Sweden).
Plates were washed with PBS/0.05% Tween 20 and incubated with
an avidin-peroxidase complex (Vectastain ABC Kit, Vector Labora-
tories, Burlingame, CA) for 45 min at room temperature. Plates
were washed with 0.05% Tween 20/PBS and PBS alone to remove
unbound complexes followed by peroxidase staining with diami-
nobenzidine solution (Sigma, St. Louis, MO) for 5 min at RT. IFN-γ
spot-forming cells (SFC) were enumerated using an AID ELISPOT
reader (Cell Technology, Columbia, MD). Results reported repre-
sent mean values of duplicates and are expressed as spot forming
cells/106 PBMC. T cell responses were considered positive after
subtraction of the mean number of spots stimulated by DC alone
from the mean number of spots induced by peptide-loaded DC.
Mature DC loaded with the control EBV peptide stimulated the
following SFC/106 PBMC: 4947122 (early post-SC), 927766 (late
post-SC), 11007264 (early cART) and 997762 (late cART).
Statistical analysis
The following statistical analyses were carried out: Pearson
correlation between (1) predicted (IC50) and experimental
(log IC50) MHC binding, (2) viral load and divergence and diversity,
(3) MHC binding and magnitude of T cell responses, (4) MHC
binding and percent positive T cell responses, (5) the frequency of
occurrence of variants and the percent positive T cell responses. In
addition, a two-tailed paired-T test was used to compare the
proportion of positive primary responses in our study participant
as well as to compare subject 8 primary responses targeting
naturally evolving sequences to those observed against the same
sequences when testing our priming model with cells from two
healthy donors. Bonferroni posthoc comparisons were applied to
compare memory responses targeting contemporaneous Gag, Env
and Nef variant sequences at early, late, early ART or late ART time
intervals. Statistical analyses were conducted using GraphPad
Prism software (version 4) and SPSS software (version 17.0).
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